Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.7146
- Book/Share 20.7566
- PB 4.1794
- Debt/Equity 0.798
- CurrentRatio 1.6612
- ROIC 0.2431
- MktCap 218020510675.0
- FreeCF/Share 5.2238
- PFCF 16.7078
- PE 11.385
- Debt/Assets 0.372
- DivYield 0.0373
- ROE 0.3895
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MRK | Citigroup | -- | Neutral | -- | $95 | Oct. 13, 2025 |
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
News
Merck Animal Health announces $895 million investment in Kansas
Published: May 08, 2025 by: Reuters
Sentiment: Positive
Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas.
Read More
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health's manufacturing facility in De Soto, Kansas. The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It inc.
Read More
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bank of America 2025 Global Healthcare Conference.
Read More
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Should Investors Buy Merck Stock After These Huge Risks?
Published: April 30, 2025 by: The Motley Fool
Sentiment: Neutral
The performance of healthcare companies is relatively uncorrelated with broader macroeconomic growth.
Read More
3 Names I Picked Up In The Latest Market Slump
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive
When the market is reaching toward all-time highs, I tend to start building a cash pile. When the market starts to get quite volatile and brings declines, that can create opportunities for putting some of that cash to work. With April's market slump, putting cash to work is exactly what I was doing; today, we are looking at 3 of the names that I added to during this market decline.
Read More
Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda
Published: April 29, 2025 by: New York Post
Sentiment: Positive
The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house US site to make the blockbuster cancer treatment, the company said.
Read More
Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports
Published: April 29, 2025 by: Reuters
Sentiment: Positive
U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall Street Journal reported on Tuesday.
Read More
Merck will build a $1 billion plant to expand U.S. manufacturing as tariff threats loom
Published: April 29, 2025 by: WSJ
Sentiment: Positive
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Read More
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Read More
2 Must-Own Dividends At Bargain Basement Prices
Published: April 28, 2025 by: Seeking Alpha
Sentiment: Positive
April's market volatility has created dividend bargains, allowing investors to pick high-quality blue-chip stocks with strong balance sheets and long-term return potential. Merck, trading at a low P/E of 9.3 and yielding 4.1%, carries a strong late-stage pipeline of 20 drugs. Schlumberger, with a P/E of 10.2 and a 3.3% yield, offers resilient growth prospects in offshore production and digital solutions.
Read More
Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal
Published: April 28, 2025 by: WSJ
Sentiment: Positive
The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.
Read More
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Published: April 27, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as pa.
Read More
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility. In fact, it's still a great time to invest in companies that have excellent underlying businesses and attractive long-term prospects.
Read More
Merck & Co., Inc. (MRK) Q1 2025 Earnings Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Corporate Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dean Li - President of Merck Research Labs Conference Call Participants Geoff Meacham - Citi Tim Anderson - Bank of America Luisa Hector - Berenberg Vamil Divan - Guggenheim Securities Chris Schott - JPMorgan James Shin - Deutsche Bank Steve Scala - TD Cowen Alex Hammond - Wolfe Research Umer Raffat - Evercore Akash Tewari - Jefferies Mohit Bansal …
Read More
Merck (MRK) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Merck lowers profit outlook due to expected $200M tariff hit
Published: April 24, 2025 by: Proactive Investors
Sentiment: Negative
Merck & Co Inc (NYSE:MRK, ETR:6MK) has lowered its full-year earnings forecast due to an expected $200 million hit from global tariffs, notably levies between the US and China. The company now expects 2025 earnings per share (EPS) in the range of $8.82 to $8.97, down from its prior forecast of $8.88 to $9.03.
Read More
2 Blue-Chip Stocks Brushing Off Earnings Beats
Published: April 24, 2025 by: Schaeffers Research
Sentiment: Negative
Pharmaceutical giant Merck & Co Inc (NYSE:MRK) has reversed its premarket lead, down 2% at $77.20 at last glance.
Read More
Cramer's Mad Dash: Merck
Published: April 24, 2025 by: CNBC Television
Sentiment: Neutral
Jim Cramer breaks down why he's keeping an eye on shares of Merck.
Read More
Merck absorbs $200 million in tariff costs into its earnings and full-year outlook
Published: April 24, 2025 by: Market Watch
Sentiment: Neutral
Shares of Merck & Co. were headed higher in early Thursday trading, after the drugmaker extended its long streak of quarterly earnings beats and held firm with its full-year outlook despite expected tariff costs.
Read More
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
Published: April 23, 2025 by: Benzinga
Sentiment: Negative
Merck & Co Inc MRK will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.
Read More
The Setup: Chipotle, United Rentals, Merck and Pepsi
Published: April 23, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you The Setup on some key names reporting this week.
Read More
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Read More
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock.
Read More
Merck & Co.: Pipeline Resilience To Unlock Value
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk.
Read More
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields approaching 8%. Trade War Realities: Despite severe pessimism driven by historic tariff increases (highest since 1909), the actual economic impact might be significantly less dire, potentially avoiding recession altogether. Institutional strategies, such as pensions and risk parity funds, may soon trigger substantial stock-buying due to automatic rebalancing. This would provide strong support and fuel market rallies from oversold conditions.
Read More
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142992&wire=1 or contact Joseph E. Levi, Esq.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
MRK DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000